In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.
about
Air pollution and circulating biomarkers of oxidative stressRole of Oxidative Stress in the Pathogenesis of Pancreatitis: Effect of Antioxidant Therapy.The atherogenic index of plasma and the risk of mortality in incident dialysis patients: Results from a nationwide prospective cohort in Korea.Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice.Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthmaTreatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function.Abdominal obesity is associated with peripheral artery disease in hemodialysis patients.HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients.High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids.Uremia alters HDL composition and functionHigh-calorie diet partially ameliorates dysregulation of intrarenal lipid metabolism in remnant kidney.Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.Serum amyloid A in uremic HDL promotes inflammationHigh Density Lipoprotein and it's DysfunctionApolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production.Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney diseaseRole of HDL dysfunction in end-stage renal disease: a double-edged sword.HDL as a biomarker, potential therapeutic target, and therapyAtherosclerosis in chronic kidney disease: the role of macrophagesHDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.Statins in the management of dyslipidemia associated with chronic kidney disease.Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research.Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease.High-density lipoprotein mimetics: promises and challenges.Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients.Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis.Synthetic Amphipathic Helical Peptides Targeting CD36 Attenuate Lipopolysaccharide-Induced Inflammation and Acute Lung Injury.Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension.Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids.HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL.Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.Downregulation of the renal and hepatic hydrogen sulfide (H2S)-producing enzymes and capacity in chronic kidney disease.Apolipoprotein A-I mimetic peptide 4F suppresses tumor-associated macrophages and pancreatic cancer progression.High-Density Lipoprotein in Chronic Kidney Diseases-The Devil Is in the Detail.Beer elicits vasculoprotective effects through Akt/eNOS activation.
P2860
Q28708793-142E1A1A-E12F-4EE1-ADFF-626BF3728B8EQ33565856-680A8C3D-BF9F-49C9-B64B-E52760851C06Q33732285-2C29E0B6-1E0A-4692-A7F3-B98C9813A44FQ34308238-ECE95AE4-EE12-4696-B01C-A012DC56E828Q34359284-89DABCCD-FC32-4C41-9B0C-3EAEFE97B1E0Q34449116-04CAB848-9832-4B0F-9CA1-5BD7D0941C65Q34503423-3AC1EA55-F938-4374-8161-1FCDA01A0C3AQ34807672-26164508-5E12-4A49-9D4A-806369BCACC0Q35027220-597E411E-7B94-478D-AB4A-536ABF81026BQ35138355-85750147-8477-4DC2-A107-3032E7F395E9Q35210194-8531ECFB-69BC-45CC-81B4-F9DAE4A62056Q35500577-9866FDC2-8B87-4C55-82AF-DA4E8C270762Q35747579-043690FA-CE5E-4FBC-8564-5E1077470F60Q35917487-3AC21995-7412-46B4-9BD9-07885CF3D35DQ36150462-11177FF3-4714-4E5A-93D7-060409C004DFQ36282246-09C0C768-A189-4580-9EB7-B6544D0E202AQ36721867-D9617CA2-33AD-4A4D-8728-BE6A72C1F53DQ36788430-B677C5E0-8A30-4741-872F-68533639303EQ36876162-6C41061E-0C5E-4D3B-BF17-EED601E819D6Q37429173-CCD96A5B-632F-40E9-84DF-056FB459C8D5Q37811885-18AB5BA7-9CCF-4147-A3D7-E5402B8B30F9Q37838234-797906D8-8A2A-4886-BCE0-F64B944CA0C2Q37986355-02584589-B6FA-4EB6-A4F7-D07D5BC1A9C5Q38076217-74235444-319F-48D3-B898-54D9A74200B2Q38084913-32BDAEAF-8622-4FE0-B3C5-7E5EEE79939FQ38111810-28E626A7-E99A-43A9-8C5E-18CCB481C9AFQ38131300-68595CF6-8C27-4242-A380-16990B6E12B1Q38220761-B5FD487F-28D8-465A-95E7-A86C035E309EQ38650575-8BA30D7F-5B61-4994-B98E-05E1412AD09AQ38758014-B1DC96BB-B899-455B-8BCC-8D78BEA7B651Q38817786-BD77EB5B-3235-4AFD-A1DA-F6BFACB0283CQ39674456-3A17681E-2C88-40A6-962E-0BBD8FDA2297Q40178749-3A120ED3-5D30-4ED7-8A6A-FD91B19239BAQ41974849-3101EFF4-304B-4405-920A-544DA6FA65EEQ42654265-DC02B06E-6073-46FC-8714-6E235D5B52EDQ43247391-4E1FA7BA-B883-486C-A8D9-3205A822C49AQ45986959-28F7FBCD-BBC1-47E7-BB5B-C591D454A341Q47138404-035D5B10-212C-4427-9DA1-6B2D90BC6F08Q52374541-44D65F87-0897-4E88-B5DA-A11728B9294DQ54314939-00A379DC-2BD3-4F9E-9E0E-354EB35C87EA
P2860
In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
In vitro stimulation of HDL an ...... by an apoA-1 mimetic peptide.
@ast
In vitro stimulation of HDL an ...... by an apoA-1 mimetic peptide.
@en
type
label
In vitro stimulation of HDL an ...... by an apoA-1 mimetic peptide.
@ast
In vitro stimulation of HDL an ...... by an apoA-1 mimetic peptide.
@en
prefLabel
In vitro stimulation of HDL an ...... by an apoA-1 mimetic peptide.
@ast
In vitro stimulation of HDL an ...... by an apoA-1 mimetic peptide.
@en
P2093
P2860
P356
P1433
P1476
In vitro stimulation of HDL an ...... by an apoA-1 mimetic peptide.
@en
P2093
Alan M Fogelman
Hamid Moradi
Madeleine V Pahl
Mohamad Navab
Nosratola D Vaziri
P2860
P2888
P304
P356
10.1038/KI.2009.177
P407
P577
2009-05-27T00:00:00Z